Literature DB >> 11735247

Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein.

D Ayalon1, T Glaser, H Werner.   

Abstract

Chromosomal translocations that disrupt the molecular organization of transcription factors are typical of a variety of solid and hematopoietic cancers. Alveolar rhabdomyosarcoma (ARMS), a paediatric soft tissue malignant tumour, is characterized by the recurrent translocation t(2;13)(q35;q14) that fuses the 5' DNA binding domain-encoding sequences of the Pax3 gene with the 3' sequences of the FKHR gene. The insulin-like growth factor (IGF) system has an important role in muscle development as well as in the aetiology of paediatric sarcomas, including ARMS. In the present study the potential regulation of the IGF-I receptor (IGF-I-R) gene by PAX3-FKHR at the transcriptional level was investigated. PAX3-FKHR was able to transactivate the IGF-I-R promoter in sarcoma-derived cell lines, whereas PAX3 exhibited a reduced potency in comparison to the fusion protein. Furthermore, transfection of the chimera induced a significant increase in the endogenous levels of IGF-I-R protein, suggesting that the IGF-I-R gene is a physiologically-relevant molecular target for the PAX3-FKHR oncogene. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735247     DOI: 10.1054/ghir.2001.0244

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  35 in total

Review 1.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 2.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

Review 3.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

4.  Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.

Authors:  Brenda Weigel; Suman Malempati; Joel M Reid; Stephan D Voss; Steven Y Cho; Helen X Chen; Mark Krailo; Doojduen Villaluna; Peter C Adamson; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2013-08-17       Impact factor: 3.167

Review 5.  Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Authors:  Helen King; Tamara Aleksic; Paul Haluska; Valentine M Macaulay
Journal:  Cancer Treat Rev       Date:  2014-08-04       Impact factor: 12.111

6.  Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.

Authors:  Fiorella Faggi; Nicola Chiarelli; Marina Colombi; Stefania Mitola; Roberto Ronca; Luca Madaro; Marina Bouche; Pietro L Poliani; Marika Vezzoli; Francesca Longhena; Eugenio Monti; Barbara Salani; Davide Maggi; Charles Keller; Alessandro Fanzani
Journal:  Lab Invest       Date:  2015-03-30       Impact factor: 5.662

Review 7.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Suman Malempati; Brenda J Weigel; Yueh-Yun Chi; Jing Tian; James R Anderson; David M Parham; Lisa A Teot; David A Rodeberg; Torunn I Yock; Barry L Shulkin; Sheri L Spunt; William H Meyer; Douglas S Hawkins
Journal:  Cancer       Date:  2018-10-23       Impact factor: 6.860

9.  The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Authors:  Raushan T Kurmasheva; Lorina Dudkin; Catherine Billups; Larisa V Debelenko; Christopher L Morton; Peter J Houghton
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

10.  Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging.

Authors:  Priyanka Jha; Andreas M J Frölich; Beth McCarville; Oscar M Navarro; Paul Babyn; Robert Goldsby; Heike Daldrup-Link
Journal:  Pediatr Radiol       Date:  2010-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.